CTCTRAP
Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients
| Coordinatore | UNIVERSITEIT TWENTE
Organization address
address: DRIENERLOLAAN 5 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 8˙321˙935 € |
| EC contributo | 6˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-09-01 - 2016-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITEIT TWENTE
Organization address
address: DRIENERLOLAAN 5 contact info |
NL (ENSCHEDE) | coordinator | 970˙000.00 |
| 2 |
LEUKOCARE AG
Organization address
address: AM KLOPFERSPITZ 19 contact info |
DE (MARTINSRIED) | participant | 810˙000.00 |
| 3 |
INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL
Organization address
address: Old Brompton Road 123 contact info |
UK (LONDON) | participant | 636˙250.00 |
| 4 |
ISTITUTO ONCOLOGICO VENETO
Organization address
address: VIA GATTAMELAYA 64 contact info |
IT (PADOVA) | participant | 636˙250.00 |
| 5 |
AQUAMARIJN MICRO FILTRATION BV
Organization address
address: BERKELKADE 11 contact info |
NL (ZUTPHEN) | participant | 610˙000.00 |
| 6 |
ASPER BIOTECH AS
Organization address
address: VAKSALI 17A contact info |
EE (TARTU) | participant | 610˙000.00 |
| 7 |
HEINRICH-HEINE-UNIVERSITAET DUESSELDORF
Organization address
address: UNIVERSITAETSSTRASSE 1 contact info |
DE (DUSSELDORF) | participant | 386˙250.00 |
| 8 |
INSTITUT GUSTAVE ROUSSY
Organization address
address: Rue Camille Desmoulins 39 contact info |
FR (VILLEJUIF) | participant | 386˙250.00 |
| 9 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 386˙250.00 |
| 10 |
MAGYAR TUDOMANYOS AKADEMIA SZEGEDI BIOLOGIAI KOZPONTJA
Organization address
address: Temesvari krt. 62 contact info |
HU (SZEGED) | participant | 383˙750.00 |
| 11 |
ACZON SRL
Organization address
address: VIA LAVINO 265 D contact info |
IT (MONTE SAN PIETRO BO) | participant | 185˙000.00 |
| 12 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven to be more effective with markedly fewer side effects. During the course of the disease alternative oncogenic signaling pathways take over inevitably leading to drug resistance. As a consequence renewed tumor analysis is required to redefine the optimal treatment regiment. However a biopsy can frequently not be obtained without risk and or discomfort to the patient. Circulating tumor cells (CTC) may circumvent this problem. CTC refer to cells that detach from a primary tumor or metastatic site, circulate in the peripheral blood and may form metastasis. CTC represent a 'liquid biopsy' that can be used to tailor treatment for individual patients. CTC are however rare and can only be obtained for further characterization in a small fraction of patients. In the CTCtrap consortium universities, research institutions and SMEs are linked in a common effort, starting from the simple, but innovative view of using Therapeutic Apheresis (TA), as a way to collect CTC from peripheral blood in cancer patients. A new TA column will be developed to capture CTC and then reintroduce the blood devoid of tumor cells back into the body with the promise to obtain CTC in all patients at risk for recurrence or diagnosed with metastatic disease. The molecular characterization of these CTC is expected to gather new knowledge on metastasis' mechanism, provide a risk assessment and the optimal therapy choice during the course of the disease of cancer patients. The new knowledge on CTC heterogeneity within cancer type and within individuals will allow for the tuning of CTCapheresis to specific cancer types. Prospective pilot studies will be setup to investigate the feasibility of the CTCapheresis in the clinic and their potential therapeutic benefit. Success of CTCapheresis will lead to a radical change in the diagnosis and treatment of solid tumors.'